Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients

Dupilumab therapy in Sézary syndrome misdiagnosed as atopic dermatitis: A case report

“…Nonetheless, it failed to improve the skin condition in our patient. Recently, Espinosa et al 4 have reviewed cutaneous T-cell lymphoma (CTCL) after dupilumab treatment and have suggested that dupilumab causes initial improvement but subsequent worsening or disease progression with potentially fatal outcome of MF/SS. Chiba et al 5 also reported a case of MF following dupilumab administration for misdiagnosed AD with skin lesion exacerbation.…”

“…The reason for dupilumab exacerbation of MF/SS remains unknown. Espinosa et al 4 have suggested CTCL worsening may be due to a malignant T-cell clone, resulting from depletion of tumor-suppressive, tumor-infiltrating lymphocytes, or dupilumab-resistant clones. We speculate that dupilumab-induced MF/SS progression may involve the subtle balance between the cytokine microenvironment and tumor growth.…”

“…1,2 Some reports have described very rare cases of EPF with extrafollicular lesions involving the palms and soles. 3,4 Intriguingly, little is known about nail deformity due to EPF. Here, we present two cases of classical EPF with palmoplantar lesions and nail deformity in comparison with psoriasis, which commonly shows palmoplantar lesions with nail deformity.…”

Dupilumab in HIV-positive patients: A case series report of 4 patients

“…A notable example is the recent case review describing the progression to S ezary syndrome in patients with mycosis fungoides who were given dupilumab. 6 To our knowledge, our study is the first case series conducted to assess the efficacy and safety of dupilumab in the treatment of AD in patients with well-controlled HIV/AIDS. As described in the individual case summaries, all 4 patients had significant improvement in their disease scores, and none of these patients experienced any additional adverse events, new infections, or any changes in their viral load or CD4 counts throughout the study period.…”

Progression of mycosis fungoides after treatment with dupilumab: A case report

“…These patients presented with thickening of the plaques or development of erythroderma and typical CTCL findings on skin biopsies after dupilumab. 5,6 A previously healthy 51-year-old woman with no past medical history of AD presented with one-year history of pruritic cutaneous Dupilumab is a human monoclonal antibody approved by US FDA and Brazil's ANVISA for severe and refractory AD. It binds to the IL-4 receptor-alpha.…”